.png){kind=icon}
.png){kind=icon}
Return
Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab
.png){kind=icon}
PRE
AI
T
S
H
Y
T
D
S
K
H
M
Y
T
K
H
H
T
K
N
S
H
Y
K
H
M
Y
DOI：10.1111/hepr.70232.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Statins contribute to the preservation of hepatic function and reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic liver disease; however, their clinical significance during systemic therapy for unresectable HCC remains unclear. Therefore, we investigated whether baseline statin use influences clinical outcomes in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
Keywords:
atezolizumab–bevacizumab
hepatocellular carcinoma
liver function
overall survival
statins
Journal
IF:
3.4
Papers:
4.2K
Citations:
4.9K
Organization
Cited Papers